---
title: "L-Carnosine for Pharmaceutical Market, Global Outlook and Forecast 2025-2032: Supply and Demand analysis, Regional Analysis and Competitive"
datePublished: Sun Nov 09 2025 12:28:35 GMT+0000 (Coordinated Universal Time)
cuid: cmhrowbng000202kv6hvi4e4x
slug: l-carnosine-for-pharmaceutical-market-global-outlook-and-forecast-2025-2032-supply-and-demand-analysis-regional-analysis-and-competitive-1-1

---

# L-Carnosine for Pharmaceutical Market, Global Outlook and Forecast 2025-2032: Supply and Demand analysis, Regional Analysis and Competitive

<p>
</p><p><strong>MARKET INSIGHTS</strong></p><p>
</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/284317/l-carnosine-for-pharmaceutical-market">
            https://www.24chemicalresearch.com/download-sample/284317/l-carnosine-for-pharmaceutical-market</a></b></div><br><p>Global L-Carnosine for Pharmaceutical market size was valued at USD 5 million in 2023. The market is projected to grow from USD 5.35 million in 2025 to USD 8.10 million by 2032, exhibiting a CAGR of 5.50% during the forecast period.</p><p>
</p><p>L-Carnosine is a naturally occurring dipeptide composed of beta-alanine and histidine, recognized for its <strong>antioxidant</strong> and <strong>anti-glycation</strong> properties. This pharmaceutical-grade compound plays a crucial role in cellular protection against oxidative stress, making it valuable for applications in dietary supplements, anti-aging formulations, and as an additive in neurological therapies. While its primary function involves combating free radicals, emerging research highlights its potential in supporting <strong>cognitive health</strong> and <strong>muscle performance</strong>.</p><p>
</p><p>The market growth is driven by increasing consumer awareness about preventive healthcare and the rising demand for anti-aging solutions. However, regulatory challenges in some regions and the relatively high production costs of high-purity L-Carnosine present hurdles for market expansion. North America currently dominates the market with a 2023 valuation of USD 1.43 million, though Asia-Pacific is expected to witness accelerated growth due to expanding pharmaceutical manufacturing capabilities in countries like China and India.</p><p>
</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Growing Anti-Aging Applications Fueling Demand for L-Carnosine</strong></p><p>
</p><p>The global anti-aging market is experiencing rapid expansion, projected to exceed $90 billion by 2030, creating substantial opportunities for L-Carnosine as a key bioactive ingredient. This dipeptide's ability to protect cellular membranes from oxidative damage and extend cellular lifespan positions it as a scientifically validated anti-aging compound. Clinical studies demonstrate its effectiveness in reducing advanced glycation end-products (AGEs), which contribute significantly to visible aging signs. Pharmaceutical formulations incorporating L-Carnosine are gaining traction in dermatological applications, with leading skincare brands increasingly incorporating this molecule into professional-grade treatments and prescription formulations.</p><p>
</p><p style="text-align:center"><strong>Expanding Neurological Applications Driving Therapeutic Adoption</strong></p><p>
</p><p>Research breakthroughs in neurological applications are creating new growth avenues for L-Carnosine. The compound exhibits neuroprotective properties through multiple mechanisms, including chelation of transition metals, scavenging of reactive oxygen species, and inhibition of protein cross-linking. Recent clinical trials have shown promising results in cognitive enhancement, with particular relevance to neurodegenerative conditions affecting over 50 million people globally. The pharmaceutical industry is actively developing L-Carnosine-based formulations for conditions including Alzheimer's disease, Parkinson's disease, and age-related cognitive decline, supported by growing evidence of its ability to modulate neuronal excitability and protect against excitotoxic damage.</p><p>
</p><p style="text-align:center"><strong>Increasing Prevalence of Metabolic Disorders Enhancing Market Growth</strong></p><p>
</p><p>The global diabetic population has surpassed 500 million, creating urgent needs for advanced therapeutic interventions where L-Carnosine demonstrates significant potential. Scientific literature extensively documents its role in reducing diabetic complications through multiple pathways including inhibition of protein glycation, reduction of oxidative stress, and improvement of endothelial function. Pharmaceutical companies are increasingly incorporating L-Carnosine into combination therapies aimed at diabetic nephropathy, retinopathy, and cardiovascular complications. Ongoing Phase III clinical trials investigating its efficacy in metabolic syndrome management indicate growing recognition of its therapeutic value beyond traditional applications.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>High Production Costs Restricting Market Accessibility</strong></p><p>
</p><p>The complex synthesis process for pharmaceutical-grade L-Carnosine creates significant cost barriers, with current production costs approximately 30-40% higher than comparable therapeutic peptides. The requirement for ultra-pure (â¥99%) material in pharmaceutical applications necessitates specialized manufacturing facilities and stringent quality control measures. These factors contribute to final product prices that remain prohibitive for widespread adoption in many healthcare systems, particularly in developing regions where reimbursement structures cannot accommodate premium-priced nutraceutical interventions. Industry analysis indicates production costs must decrease by at least 25% to achieve broader market penetration.</p><p>
</p><p><strong>Regulatory Complexities in Product Classification</strong></p><p>
The dual classification of L-Carnosine as both a pharmaceutical ingredient and dietary supplement creates regulatory ambiguities that complicate market development. Jurisdictional differences in approval pathways lead to fragmented market entry strategies, with some regions requiring full drug approval processes while others permit supplement classification. These inconsistencies force manufacturers to maintain parallel development tracks, significantly increasing compliance costs and time-to-market.</p><p>
</p><p><strong>Limited Long-Term Clinical Data</strong></p><p>
While short-term safety profiles are well-established, comprehensive longitudinal studies exceeding five years remain limited for many therapeutic applications. This data gap creates hesitation among conservative prescribers and formulary committees evaluating L-Carnosine for chronic conditions requiring extended use. The absence of decade-long safety monitoring studies particularly impacts acceptance in pediatric and geriatric populations where metabolic considerations are most critical.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Bioavailability Limitations Constraining Efficacy</strong></p><p>
</p><p>L-Carnosine's therapeutic potential is significantly limited by its rapid degradation by serum carnosinase, with oral bioavailability typically below 15% in human subjects. This pharmacokinetic challenge restricts achievable plasma concentrations and duration of action, requiring frequent high-dose administration or specialized delivery systems. While prodrug formulations and absorption enhancers show promise in preclinical studies, translation to clinical practice has been slow due to formulation stability challenges and regulatory concerns about excipient safety. These limitations currently prevent full realization of L-Carnosine's mechanistic potential across multiple therapeutic areas.</p><p>
</p><p style="text-align:center"><strong>Intellectual Property Barriers Inhibiting Innovation</strong></p><p>
</p><p>The expiration of foundational patents has created an environment where composition-of-matter protections are difficult to obtain, discouraging investment in novel formulations. While delivery system patents offer some protection, the relatively short remaining exclusivity periods for these secondary patents provide insufficient ROI timelines for many pharmaceutical developers. This has resulted in a market dominated by generic formulations, with limited incentive for therapeutic innovation beyond incremental improvements in existing delivery technologies.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Advancements in Delivery Technologies Creating New Potential</strong></p><p>
</p><p>Emerging drug delivery platforms present transformative opportunities for L-Carnosine pharmaceuticals. Liposomal encapsulation technologies have demonstrated the ability to enhance oral bioavailability to approximately 65% in recent pharmacokinetic studies, while novel nasal delivery systems show promising CNS targeting capabilities. These technological breakthroughs coincide with growing physician acceptance of advanced delivery systems, creating a receptive environment for next-generation L-Carnosine formulations. Industry projections indicate the market for enhanced-bioavailability peptide therapeutics will exceed $12 billion by 2030, with L-Carnosine positioned to capture significant share.</p><p>
</p><p style="text-align:center"><strong>Expansion into Emerging Therapeutic Areas</strong></p><p>
</p><p>Recent discoveries in ophthalmology and auditory medicine are uncovering new applications for L-Carnosine therapeutics. Clinical trials investigating its efficacy in noise-induced hearing loss have shown statistically significant protection against cochlear damage, while ophthalmic formulations demonstrate potential in delaying cataract progression. These niche applications represent high-value opportunities with less pricing sensitivity than broader metabolic indications. Theç¼ç§market alone for cataract prevention is projected to reach $35 billion globally by 2030, creating substantial commercial potential for specialized L-Carnosine formulations.</p><p>
</p><p style="text-align:center"><strong>Strategic Partnerships Accelerating Commercialization</strong></p><p>
</p><p>Vertical integration between manufacturers and academic institutions is accelerating translation of basic research into commercial products. Leading pharmaceutical companies are establishing dedicated L-Carnosine research partnerships with top-tier universities, combining academic expertise with industrial-scale development capabilities. These collaborations are particularly focused on overcoming bioavailability challenges and expanding patent portfolios through formulation innovation. Recent licensing deals in this space have reached valuations exceeding $150 million, reflecting growing confidence in L-Carnosine's commercial potential across multiple therapeutic domains.</p><p>
</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>High-Purity L-Carnosine (â¥99%) Gains Traction Due to Stringent Pharmaceutical Standards</strong></p><p>
</p><p>The market is segmented based on type into:</p><p>
</p><p>High-Purity L-Carnosine (â¥99%)</p><p>Standard Purity L-Carnosine (98-99%)</p><p>Pharmaceutical-Grade Complex Formulations</p><p>Others</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Neurological Therapeutics Segment Expands with Rising Research on Cognitive Health</strong></p><p>
</p><p>The market is segmented based on application into:</p><p>
</p><p>Neurological Therapeutics</p><p>Anti-Aging Formulations</p><p>Metabolic Disorder Treatments</p><p>Dietary Supplements</p><p>Others</p><p>
<strong>By Form</strong></p><p>
</p><p><strong>Powdered Form Dominates Due to Manufacturing Flexibility</strong></p><p>
</p><p>The market is segmented based on form into:</p><p>
</p><p>Powder</p><p>Capsules</p><p>Tablets</p><p>Liquid Solutions</p><p>
<strong>By End User</strong></p><p>
</p><p><strong>Contract Research Organizations Show Significant Adoption for Clinical Trials</strong></p><p>
</p><p>The market is segmented based on end user into:</p><p>
</p><p>Pharmaceutical Companies</p><p>Nutraceutical Manufacturers</p><p>Contract Research Organizations</p><p>Academic Research Institutes</p><p>

<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Strategic Partnerships and Product Innovation Drive Market Competition</strong></p><p>
</p><p>The global L-Carnosine for pharmaceutical market exhibits a <strong>fragmented competitive landscape</strong>, with a mix of established players and emerging regional suppliers competing on quality, price, and purity standards. <strong>Bachem AG</strong>, as a global peptide specialist, dominates the high-purity segment with its GMP-certified production facilities in Switzerland and the United States. The company's 2024 expansion of its L-Carnosine production capacity by 35% strengthened its position as a supplier for clinical-grade applications.</p><p>
</p><p>Meanwhile, <strong>Fushilai Pharmaceutical</strong> and <strong>Hamari Chemicals</strong> captured significant market share in Asia-Pacific through cost-competitive manufacturing and strong distribution networks. These companies collectively accounted for approximately 28% regional market share in 2024 according to industry analysts, benefiting from increasing domestic demand in China and Japan for dietary supplements.</p><p>
</p><p>Strategic movements in 2025 include <strong>Xi'an Miracle Biotechnology's</strong> partnership with European distributors to expand beyond its traditional domestic market, while <strong>SUANFARMA</strong> launched a new 99.5% purity pharmaceutical-grade L-Carnosine line targeting neurodegenerative disease research applications. These developments reflect the industry's shift toward specialized, high-margin product segments.</p><p>
</p><p>Competitive intensity is further heightened by <strong>KS-V Peptide's</strong> recent FDA facility certification and <strong>Belle Chemical's</strong> vertical integration strategy, controlling raw material sourcing to optimize production costs. Such moves are reshaping supply chain dynamics as companies position themselves for the projected 5.5% CAGR growth through 2032.</p><p>
<strong>List of Key L-Carnosine Manufacturers Profiled</strong></p><p>
</p><p>Bachem AG (Switzerland)</p><p>Fushilai Pharmaceutical Co., Ltd. (China)</p><p>Hamari Chemicals, Ltd. (Japan)</p><p>SUANFARMA (Spain)</p><p>Xi'an Miracle Biotechnology Co., Ltd. (China)</p><p>Belle Chemical LLC (U.S.)</p><p>KS-V Peptide (China)</p><p>Sinoway Industrial Co., Ltd. (China)</p><p>
</p><p>The competitive environment continues evolving as mid-sized players adopt API+ formulations strategies, combining L-Carnosine with complementary bioactives to differentiate their offerings. With neurological health applications gaining research traction, companies investing in clinical validation studies are expected to gain competitive advantage in the pharmaceutical segment through 2032.</p><p>
<strong>L-CARNOSINE FOR PHARMACEUTICAL MARKET TRENDS</strong></p><p>
<strong>Anti-Aging and Neurological Applications Drive Market Expansion</strong></p><p>
</p><p>The global L-Carnosine market is witnessing accelerated growth due to rising demand for its anti-aging and neuroprotective properties. Clinical studies demonstrate that this dipeptide antioxidant significantly reduces oxidative stress and glycation end-products, which are key factors in cellular aging. Pharmaceutical companies are increasingly incorporating L-Carnosine in formulations targeting age-related conditions, particularly in ophthalmology where it shows promise for cataract prevention. Furthermore, emerging research on its ability to enhance cognitive function is creating new therapeutic opportunities in neurodegenerative diseases like Alzheimer's and Parkinson's. The market is projected to grow at 5.50% CAGR from 2024-2032, reaching $8.10 million, with neurological applications accounting for an estimated 32% of total demand by 2025.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Metabolic Disorder Therapeutics</strong></p><p>
</p><p>L-Carnosine is gaining recognition as an adjunct therapy for metabolic disorders including diabetes and cardiovascular diseases. Its ability to regulate glucose metabolism and protect against diabetic complications is driving adoption in pharmaceutical formulations. Recent studies indicate L-Carnosine supplementation can lower HbA1c levels by 0.8-1.2% in type 2 diabetes patients, making it a valuable component in comprehensive treatment plans. The compound's role in preventing advanced glycation end-product formation presents significant opportunities in diabetic nephropathy and retinopathy treatments, which together represent a potential $1.2 billion addressable market globally.</p><p>
<strong>Nutraceutical Synergy and Combination Therapies</strong></p><p>
</p><p>Pharmaceutical manufacturers are increasingly combining L-Carnosine with other bioactive compounds to enhance therapeutic efficacy. Notable combinations include zinc-L-Carnosine complexes for gastrointestinal protection and formulations blending carnosine with established antioxidants like glutathione. This synergy approach is particularly prominent in Asia-Pacific markets, where combination nutraceuticals account for 45% of product launches. The trend reflects growing consumer preference for multi-functional supplements and physician recommendations for adjunctive therapies. Clinical evidence supporting these combinations has led to a 28% increase in patent filings for carnosine-based formulations between 2020-2024, indicating robust innovation activity in this segment.</p><p>
</p><p>
<strong>Regional Analysis: L-Carnosine for Pharmaceutical Market</strong></p><p>

  
    North America
    
      North America dominates the pharmaceutical-grade L-Carnosine market, valued at approximately USD 1.43 million in 2024, with projected growth at a 4.71% CAGR through 2032. The U.S. drives over 65% of regional demand, leveraging its advanced healthcare infrastructure and strong research focus on neuroprotective and anti-aging therapies. Regulatory approvals by the FDA for L-Carnosine in dietary supplements and investigational new drug applications reinforce market stability. Major pharmaceutical companies increasingly incorporate L-Carnosine into formulations targeting cognitive health and age-related metabolic disorders.
    
  
  
  
    
      Therapeutic Applications</p><p>
      L-Carnosine's primary use cases include neurodegenerative disease research (particularly Alzheimerâs and Parkinsonâs), anti-aging formulations, and diabetic complication management. Over 120 clinical trials registered with the U.S. National Institutes of Health involve L-Carnosine as an intervention.
    
    
      Supply Chain Dynamics</p><p>
      The region benefits from localized production by vendors like Belle Chemical and Bachem, ensuring consistent API supply. However, dependency on Chinese raw material imports for synthetic L-Carnosine remains a vulnerability during trade disruptions.
    
    
      Innovation Trends</p><p>
      Emerging delivery mechanisms include nanoparticle-encapsulated L-Carnosine for enhanced bioavailability, with several patents filed in 2024. Partnerships between nutraceutical brands and biotech firms aim to develop combination therapies for metabolic syndromes.
    
    
      Market Barriers</p><p>
      High production costs for pharmaceutical-grade purity (â¥99%) and limited physician awareness of clinical benefits constrain broader adoption. Off-label use in wellness products also creates regulatory ambiguities for manufacturers.
    
  
</p><p>
</p><p><strong>Europe</strong></p><p>
Europe holds the second-largest market share, with Germany and France leading in L-Carnosine research applications. The European Medicines Agency's (EMA) 2023 guidelines on antioxidant supplements have standardized quality requirements, boosting demand for high-purity grades. The region shows strong growth in cosmeceuticals, where L-Carnosine is used for anti-glycation skincare formulations. However, strict advertising restrictions for non-approved health claims limit consumer education efforts.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
China and Japan account for over 50% of regional consumption, driven by traditional medicine integration and government-funded aging population studies. India's market is expanding at 6.2% CAGR, with growing middle-class demand for preventive health supplements. Local manufacturers like Fushilai Pharmaceutical dominate low-cost production, but quality inconsistencies pose challenges for pharmaceutical applications requiring GMP compliance.</p><p>
</p><p><strong>South America</strong></p><p>
Brazil represents the largest consumer, utilizing L-Carnosine primarily in sports nutrition and metabolic health supplements. However, regulatory fragmentation across countries and economic instability limit investment in clinical-grade formulations. The region relies heavily on imports, with over 70% of supply sourced from China and Europe.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
The GCC countries lead in market growth, fueled by medical tourism and specialty clinics offering longevity therapies. South Africa shows nascent demand for imported neuroprotective supplements, though low physician awareness and counterfeit products hinder market development. Regional production is virtually nonexistent, creating import dependency.</p><p>


</p><p><strong>Key Report Takeaways</strong></p><p>
</p><p>
</p><p>
</p><p>
</p><p>
</p><p>
<strong>Report Scope</strong></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for L-Carnosine for Pharmaceutical applications, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed L-Carnosine for Pharmaceutical companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global L-Carnosine for Pharmaceutical Market?</strong></p><p>
</p><p><strong>-&gt;</strong> Global L-Carnosine for Pharmaceutical market was valued at <strong>USD 5 million in 2023</strong> and is projected to reach <strong>USD 8.10 million by 2032</strong>, growing at a CAGR of 5.50% during the forecast period.</p><p>
<strong>Which key companies operate in Global L-Carnosine for Pharmaceutical Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>Fushilai Pharmaceutical, Hamari Chemicals, Sinoway Industrial, Bachem, Belle Chemical, Xi'an Miracle Biotechnology, SUANFARMA, and KS-V Peptide</strong>, among others.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include <strong>rising demand for anti-aging products, increasing applications in neurological therapies, and growing awareness about cellular health benefits</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; North America</strong> currently leads the market with <strong>USD 1.43 million valuation in 2023</strong>, while <strong>Asia-Pacific</strong> is expected to show the fastest growth due to expanding pharmaceutical manufacturing capabilities.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include <strong>development of high-purity formulations, increased research into cognitive health applications, and expansion in functional food additives</strong>.</p><p>
</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/284317/l-carnosine-for-pharmaceutical-market">
            https://www.24chemicalresearch.com/reports/284317/l-carnosine-for-pharmaceutical-market</a></b></div><br>
            <b>Table of Content:</b><p>Table of Contents<br />
1 Research Methodology and Statistical Scope<br />
1.1 Market Definition and Statistical Scope of L-Carnosine for Pharmaceutical<br />
1.2 Key Market Segments<br />
1.2.1 L-Carnosine for Pharmaceutical Segment by Type<br />
1.2.2 L-Carnosine for Pharmaceutical Segment by Application<br />
1.3 Methodology & Sources of Information<br />
1.3.1 Research Methodology<br />
1.3.2 Research Process<br />
1.3.3 Market Breakdown and Data Triangulation<br />
1.3.4 Base Year<br />
1.3.5 Report Assumptions & Caveats<br />
2 L-Carnosine for Pharmaceutical Market Overview<br />
2.1 Global Market Overview<br />
2.1.1 Global L-Carnosine for Pharmaceutical Market Size (M USD) Estimates and Forecasts (2019-2032)<br />
2.1.2 Global L-Carnosine for Pharmaceutical Sales Estimates and Forecasts (2019-2032)<br />
2.2 Market Segment Executive Summary<br />
2.3 Global Market Size by Region<br />
3 L-Carnosine for Pharmaceutical Market Competitive Landscape<br />
3.1 Global L-Carnosine for Pharmaceutical Sales by Manufacturers (2019-2024)<br />
3.2 Global L-Carnosine for Pharmaceutical Revenue Market Share by Manufacturers (2019-2024)<br />
3.3 L-Carnosine for Pharmaceutical Market Share by Company Type (Tier 1, Tier 2, and Tier 3)<br />
3.4 Global L-Carnosine for Pharmaceutical Average Price by Manufacturers (2019-2024)<br />
3.5 Manufacturers L-Carnosine for Pharmaceutical Sales Sites, Area Served, Product Type<br />
3.6 L-Carnosine for Pharmaceutical Market Competitive Situation and Trends<br />
3.6.1 L-Carnosine for Pharmaceutical Market Concentration Rate<br />
3.6.2 Global 5 and 10 Largest L-Carnosine for Pharmaceutical Player</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/284317/l-carnosine-for-pharmaceutical-market">
            https://www.24chemicalresearch.com/reports/284317/l-carnosine-for-pharmaceutical-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>